Skip to main content
. 2021 Apr 8;6(7):e142000. doi: 10.1172/jci.insight.142000

Figure 3. Transcriptomic profiling shows minimal dose doxorubicin does not affect cardiac development pathways in ESC-CMs.

Figure 3

(A) Heatmap of gene expression levels in ESCs treated with increasing doxorubicin dosages and representative plots of gene expression levels at increasing doxorubicin dosages. (B) Heatmap of gene expression levels in ESC-CMs treated with increasing doxorubicin dosages and representative plots of gene expression levels at increasing doxorubicin dosages. (C) GoPlot of pathway enrichment and the number of genes involved in each pathway at specific doxorubicin dosages compared with untreated ESCs or ESC-CMs.